Blue test tubes arranged in a line, disappearing into the background

Drug news

EU approves subcutaneous Velcade (Janssen) for treatment of Multiple Myeloma

Read time: 1 mins

Last updated:1st Oct 2012

Published:1st Oct 2012

Source: Pharmawand

The EC has approved the subcutaneous version of Velcade (bortezomib) from J&J Janssen Cilag for Multiple Myeloma. Subcutaneous bortezomib has fewer side effects and offers greater convenience for patients, with similar efficacy compared to intravenous bortezomib.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Brain Stimulation publishes key RECOVER study data

The RECOVER clinical study published in Brain Stimulation shows that LivaNova's VNS Therapy system significantly improves depressive symptoms and quality of life in patients with treatment-resistant unipolar depression

6 mins

Drug news

FDA grants Breakthrough status to Trodelvy for SCLC

The FDA has granted Breakthrough Therapy Designation to Gilead's Trodelvy for second-line treatment of extensive-stage small cell lung cancer, based on promising results from the Phase 2 TROPiCS-03 study

1 min

Drug news

Ibrance combo boosts PFS survival by 15+ months in MBC

The Phase 3 PATINA study shows that Ibrance, combined with standard therapies, extends progression-free survival by over 15 months in HR+/HER2+ metastatic breast cancer

2 min

See all news